Coreg and Product solubility abnormal - a phase IV clinical study of FDA data

Summary:

Product solubility abnormal is reported as a side effect among people who take Coreg (carvedilol), especially for people who are male, 60+ old, also take Veltassa, and have Hyperkalemia.

The phase IV clinical study analyzes which people have Product solubility abnormal when taking Coreg. It is created by eHealthMe based on reports of 48,155 people who have side effects when taking Coreg from the FDA, and is updated regularly.

What is Coreg?

Coreg has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 49,583 Coreg users. Check the latest studies of Coreg.

What is Product solubility abnormal?

Product solubility abnormal is found to be associated with 281 drugs and 327 conditions by eHealthMe. Check the latest studies of Product solubility abnormal.

On Jul, 11, 2026

48,155 people reported to have side effects when taking Coreg.
Among them, 14 people (0.03%) have Product solubility abnormal.

Could Coreg cause Product solubility abnormal?

Among these 14 people:

What is the gender of people who have Product solubility abnormal when taking Coreg? *

female: 7.69 %
male: 92.31 %

What is the age of people who have Product solubility abnormal when taking Coreg? *

What are other drugs people take besides Coreg? *

What are other side effects people have besides Product solubility abnormal? *

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 4 people, 28.57%
Postoperative Wound Infection: 3 people, 21.43%
Diarrhea: 3 people, 21.43%
Fatigue (feeling of tiredness): 3 people, 21.43%
Memory Loss: 3 people, 21.43%
Pain In Extremity: 3 people, 21.43%
Chronic Kidney Disease: 3 people, 21.43%
Renal Impairment (severely reduced kidney function): 3 people, 21.43%
Hospitalisation: 2 people, 14.29%
Drug Ineffective: 2 people, 14.29%

What are the existing conditions these people have? *

Hyperkalemia (damage to or disease of the kidney): 7 people, 50.00%
Cardiac Disorder: 2 people, 14.29%
Type 2 Diabetes: 1 person, 7.14%
Muscle Spasms (muscle contraction): 1 person, 7.14%
Blood Uric Acid Increased: 1 person, 7.14%
Chest Pain: 1 person, 7.14%
Diabetes: 1 person, 7.14%
Erection Problems: 1 person, 7.14%
Heart Attack: 1 person, 7.14%
Neuropathy Peripheral (surface nerve damage): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Coreg and have Product solubility abnormal?

- Check whether Product solubility abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Coreg:

Coreg (49,583 reports)

Browse all side effects of Coreg:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Product solubility abnormal:

Product solubility abnormal (281 drugs)

Browse all the conditions that are associated with Product solubility abnormal:

Product solubility abnormal (327 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Coreg) and Coreg (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.